Actinic Keratosis Treatment Market to reach USD 9.7 billion by 2032, Says Graphical Research Powered by GMI
13 juin 2023 18h00 HE
|
Graphical Research
Selbyville, Delaware, June 13, 2023 (GLOBE NEWSWIRE) -- Actinic Keratosis Treatment Market size to be worth USD 9.7 billion by 2032. The industry gains is driven by the increasing cases of...
Canine Atopic Dermatitis Market Size is projected to reach USD 5.69 Billion by 2030, growing at a CAGR of 16.5%: Straits Research
03 août 2022 12h30 HE
|
Straits Research
New York, United States, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Canine Atopic Dermatitis is marked by skin irritation that lasts for a long time and a particular pattern of skin lesions. IgE antibodies...
Biofrontera reports earnings results for the third quarter and first nine months of 2018
16 nov. 2018 02h20 HE
|
Biofrontera AG
Leverkusen, Germany, Nov. 16, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its...
Biofrontera Announces Conference Call to Discuss Q3 2018 Financial Results
05 nov. 2018 06h26 HE
|
Biofrontera AG
Leverkusen, Germany, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its...
Correction of news release from August 31, 2018: Biofrontera reports significant revenue growth for the first 6 months of 2018
03 sept. 2018 05h35 HE
|
Biofrontera AG
Leverkusen, Germany, Sept. 03, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported...
Biofrontera Reports Full Year 2017 Financial Results
30 avr. 2018 08h00 HE
|
Biofrontera AG
Leverkusen, Germany, April 30, 2018 (GLOBE NEWSWIRE) --
Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (“Biofrontera” or the “Company”), an international biopharmaceutical...
Biofrontera announces preliminary unaudited sales revenues for the 1st Quarter 2018
12 avr. 2018 10h53 HE
|
Biofrontera AG
Leverkusen, Germany, April 12, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA) (ISIN: DE0006046113), the specialist for the treatment of sun-induced skin cancer, today announced preliminary...